About Renalys
Renalys is a company based in Chuo (Japan) founded in 2023 by Takeshi Takahashi and BT Slingsby was acquired by Chugai Pharmaceutical in October 2025. Renalys has raised $38.2 million across 1 funding round from investors including Chugai Pharmaceutical, Catalys Pacific and SR One. Renalys operates in a competitive market with competitors including Calliditas Therapeutics, Enyo Pharma, Unicycive, Akebia Therapeutics and Alebund, among others.
- Headquarter Chuo, Japan
- Founders Takeshi Takahashi, BT Slingsby
- SectorsHealthcare
- Website renalys.com
- Acquired by Chugai Pharmaceutical (Oct 2025)
- Total Equity Funding$38.2M (USD)
in 1 rounds
- Latest Funding Round$38.2M (USD), Series A
Jul 2024
- InvestorsChugai Pharmaceutical
& 6 more
- Acquired byChugai Pharmaceutical
(Oct 2025)
Funding Insights of Renalys
Renalys has successfully raised a total of $38.2M through 1 strategic funding round. The most recent funding activity was a Series A round of $38.2 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $38.2M
- Total Rounds 1
- Last Round Series A — $38.2M
- First Round $38.2M
(Jul 2024)
- Investors Count 6
All 1 funding rounds of Renalys with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $38.2M | Series A | – | Catalys Pacific, SR One |
7 investors in total: 7 institutional.
Investors in Renalys
Renalys has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Chugai Pharmaceutical, Catalys Pacific and SR One.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A biotechnology venture capital firm investing in innovative science. | – | srone.com | - | |
VC firm investing in Japan and the US | – | nvcc.co.jp | Chiyoda City, Japan | |
- | – | japanco-investiv.tcc.mode | - | |
Invests in biotech companies via global networks and partnerships for disease treatments. | 2019 | catalyspacific.com | Cayman Islands | |
Provides investment management services focused on portfolio construction and risk assessment. | 2018 | jp-investment.co.jp | Chiyoda City, Japan | |
Operates as a commercial bank offering deposits, loans, and payment services. | 1925 | smtb.jp | Chiyoda City, Japan | |
Innovative pharmaceutical products and services are developed and delivered. | 1925 | chugai-pharm.co.jp | Tokyo, Japan |
Investor details for Renalys
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Renalys
2 people are tracked at Renalys (2 in leadership).
| Name | Role | Group |
|---|---|---|
Takeshi Takahashi | Co-Founder | Leadership |
BT Slingsby | Co-Founder & CEO | Leadership |
Complete people profiles for Renalys
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Renalys
3 dated milestones of Renalys across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Renalys is founded.
- Funding First funding round of $38.2M.
- Exit Acquired by Chugai Pharmaceutical.
Competitors of Renalys
Renalys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Calliditas Therapeutics, Enyo Pharma, Unicycive, Akebia Therapeutics and Alebund, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| calliditas.se | 2004 | Stockholm, Sweden | $44.83M | 40 | Provider of small molecule based drug for inflammatory kidney disease | |
| enyopharma.com | 2014 | Lyon, France | $120.34M | – | Therapeutics are developed for diseases with impaired kidney function. | |
| unicycive.com | 2016 | San Francisco, United States | $1.55M | 12 | Small molecule therapies for kidney diseases are developed. | |
| akebia.com | 2007 | Cincinnati, United States | $91M | 205 | Therapeutics for kidney disease treatment are developed by Akebia Therapeutics. | |
| alebund.com | 2018 | Shanghai, China | $114.5M | – | Therapeutics for various kidney diseases are developed. | |
| auriniapharma.com | 1993 | Edmonton, Canada | – | 17 | Therapeutics for autoimmune diseases are developed by Aurinia Pharmaceuticals. | |
| purespringtx.com | 2020 | London, United Kingdom | $164M | – | Developer of therapeutics for chronic renal diseases | |
| arthrosi.com | 2017 | Irvine, United States | $200.87M | 11 | Therapeutics for gout, kidney diseases, and oncology are developed. | |
| oxthera.com | 2005 | Stockholm, Sweden | $93.1M | – | Microbial-based drug products for hyperoxaluria treatment are developed. |
Detailed competitors of Renalys
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Renalys
The website of Renalys (renalys.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▼ 41.7% vs previous month
Latest news on Renalys
Complete news archive for Renalys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Renalys
10 companies that operate in the same segment as Renalys (Metabolic Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Developer of cortisol modulators for the treatment of various diseases | 1998 | Menlo Park, California, United States | – | USD 761.41 M | 500 | |
Developer of therapies for the treatment of endocrine-related diseases and cancers | 2008 | San Diego, California, United States | USD 103.5 M | USD 1.04 M | 437 | |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | 2009 | Cambridge, Massachusetts, United States | USD 685 M | – | 81 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Solutions for biomarker discovery and diagnostic testing are provided. | 2000 | Morrisville, United States | USD 165.87 M | – | – | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Renalys
Renalys was founded in 2023 and raised its 1st funding round 1 year after it was founded.
Renalys is headquartered in Chuo, Japan. It is registered at Chuo, Yamanashi Prefecture, Japan.
BT Slingsby is the current CEO of Renalys. They have also founded this company.
Renalys is a funded company, having raised a total of $38.2M across 1 funding round to date. The company's 1st funding round was a Series A of $38.2M, raised on Jul 2024.
Renalys was established in 2023 in Chuo City, Japan, within the biotechnology sector. Focus is placed on developing therapeutics for renal diseases. Sparsentan, an oral dual endothelin angiotensin receptor antagonist, has been introduced for treating IgA nephropathy. Operations center on advancing treatments for kidney-related conditions, with co-founders Takeshi Takahashi and BT Slingsby leading efforts in this specialized field.
Renalys's top competitors include Calliditas Therapeutics, Enyo Pharma and Akebia Therapeutics.
Renalys has 7 investors. Key investors include Chugai Pharmaceutical, Catalys Pacific, SR One, JP Investment, and Sumitomo Mitsui Trust Bank.
Yes. Renalys was acquired by Chugai Pharmaceutical in October 2025.